Validation of PTEN and LZTS2 loss, as well as cellular ß-catenin expression and localization within human tumor samples will provide useful information about the roles of PTEN and LZTS2 in human tumorigenesis; this knowledge may lead to the development of new therapeutic strategies for prostate cancer and other human malignancies. Here, LZTS2 is linked to prostate carcinoma.